Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/9731
Title: | Dual antiplatelet therapy in secondary prevention of ischemic stroke: A ghost from the past or a new frontier? | Authors: | Balucani C. Barlinn K. Živanović, Željko Parnetti L. Silvestrini M. Alexandrov A. |
Issue Date: | 1-Dec-2010 | Journal: | Stroke Research and Treatment | Abstract: | With majority of ischemic strokes attributable to atherothrombosis and many being predictable after transient ischemic attacks (TIA), the role of early secondary prevention with antiplatelet agents is under renewed investigation. Prior major clinical trials of various secondary stroke prevention regimens pointed to a greater efficacy of dual antiplatelet agents if initiated early from symptom onset. This paper examines data and rationale behind dual antiplatelet regimens across the completed clinical trials. The safety of dual antiplatelets approach is of concern, but it could be outweighed, at least in early management, by a greater reduction in recurrence of ischemic events since this risk is front "loaded" after minor stroke or TIA. Aspirin monotherapy, though considered standard of care, is compared to aspirin-extended release dipiridamole and its combination with clopidogrel in early-phase completed and efficacy-phase ongoing clinical trials. © 2010 Clotilde Balucani et al. | URI: | https://open.uns.ac.rs/handle/123456789/9731 | DOI: | 10.4061/2010/427418 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
6
checked on Sep 9, 2023
Page view(s)
6
Last Week
1
1
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.